On May 12, 2025, HC Wainwright & Co. analyst Andres Maldonado reiterated a "Buy" rating for ImmunityBio (IBRX, Financial). The analyst maintained the price target at $8.00 USD, reflecting confidence in the stock's potential performance.
The decision to reaffirm the price target and rating suggests stable expectations for ImmunityBio (IBRX, Financial). The unchanged price target indicates that the analyst's outlook remains optimistic, aligning with previous evaluations.
Investors and market participants might find this consistent analysis from HC Wainwright & Co. as a sign of assurance in the company's future prospects.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for ImmunityBio Inc (IBRX, Financial) is $11.25 with a high estimate of $30.00 and a low estimate of $4.25. The average target implies an upside of 391.27% from the current price of $2.29. More detailed estimate data can be found on the ImmunityBio Inc (IBRX) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, ImmunityBio Inc's (IBRX, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for ImmunityBio Inc (IBRX, Financial) in one year is $75.81, suggesting a upside of 3210.48% from the current price of $2.29. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the ImmunityBio Inc (IBRX) Summary page.
